Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Immunocore Holdings plcNASDAQ: IMCR
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables rises 28.5% from a year ago
Net receivables stood at $81.07M at the end of Q1 FY2026, up 28.5% from a year earlier and up 9.6% from the prior quarter. Over 3 fiscal years it compounded at +9.0% a year.
Context
- Net receivables amounted to 7.6% of total assets at the end of Q1 FY2026, up 1.4 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +28.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 73.98M USD
- Year-over-year change
- -11.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.98M | -11.0% |
| FY2024 | 2024-12-31 | 83.1M | — |
| FY2023 | 2023-12-31 | 48.62M | -14.8% |
| FY2022 | 2022-12-31 | 57.08M | +70.3% |
| FY2021 | 2021-12-31 | 33.52M | — |
Net Receivables vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +28.5% is the 6th highest of 11, against a peer median of +28.9%.
- Net receivables amounts to 7.6% of total assets for IMCR, versus a peer median of 4.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €245.1M EUR | -83.1% | -48.4% | 1.2% | |
| Mar 2026 | $81.07M USD | +28.5% | +9.0% | 7.6% | |
| Sep 2026 | $53.6M USD | +59.0% | +182.5% | 8.8% | |
| Mar 2026 | $42.46M USD | +660.3% | +109.4% | 4.1% | |
| Jun 2026 | $42.23M USD | -11.2% | +0.3% | 5.8% | |
| Dec 2025 | A$37.52M AUD | +2426831.8% | -90.4% | 25.5% | |
| Jun 2026 | $36M USD | +80.0% | -28.1% | 3.9% | |
| Mar 2026 | $10.43M USD | -1.1% | -38.0% | 4.8% | |
| Dec 2025 | €7.61M EUR | +363.2% | +34.3% | 12.1% | |
| Mar 2026 | €4.82M EUR | -26.7% | +83.6% | 0.9% | |
| Mar 2026 | $2.34M USD | -25.7% | -2.5% | 1.6% | |
| Peer median (excluding IMCR) | — | +28.9% | -1.1% | 4.5% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 321.06M | 402.47M | 350.27M | 455.73M | 467.71M |
| Short-term Investments | 0 | 0 | 0 | 364.65M | 396.44M |
| Net Receivables | 33.52M | 57.08M | 48.62M | 83.1M | 73.98M |
| Inventory | 0 | 692K | 3.56M | 5.45M | 6.74M |
| Other Current Assets | (7.69M) | 3.62M | 7.68M | 7.9M | 51.87M |
| Total Current Assets | 354.58M | 473.98M | 418.48M | 929.86M | 996.74M |
| Property, Plant & Equipment (Net) | 42.56M | 38.78M | 33.82M | 47.74M | 50.25M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 410 | 0 | 0 | 0 |
| Long-term Investments | 222.69K | 137K | 0 | 0 | 0 |
| Tax Assets | 3.48M | 5.12M | 8.68M | 14.79M | 0 |
| Other Non-current Assets | 6.44M | 8.75M | 11.45M | 17.12M | 20.28M |
| Total Non-current Assets | 52.7M | 52.79M | 53.96M | 79.64M | 70.53M |
| Total Assets | 407.28M | 526.76M | 472.44M | 1.01B | 1.07B |
| Account Payables | 10.12M | 14.45M | 14.08M | 25.1M | 24.36M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.01M |
| Tax Payables | 718.01K | 1.12M | 1.43M | 0 | 0 |
| Deferred Revenue | 33M | 7.76M | 0 | 0 | 583K |
| Other Current Liabilities | 83.68K | 9.15M | 9.18M | 13.1M | 219.74M |
| Total Current Liabilities | 82.57M | 100.84M | 110.01M | 212.18M | 246.7M |
| Long-term Debt | 50.24M | 47.81M | 37.99M | 391.01M | 393.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 8.65M | 5.24M | 4.36M | 5.43M | 4.86M |
| Other Non-current Liabilities | 76.93K | 2.22M | 773.94K | 0 | 0 |
| Total Non-current Liabilities | 93.19M | 87.02M | 70.54M | 436.61M | 439.54M |
| Total Liabilities | 175.76M | 187.86M | 180.55M | 648.79M | 686.24M |
| Common Stock | 118.77K | 129K | 83.18K | 135K | 136K |
| Retained Earnings | (649.7M) | (689.39M) | (589.3M) | (795.76M) | (831.28M) |
| Accumulated OCI | 521.31M | (54.67M) | (28.7M) | (33.76M) | (28.08M) |
| Other Stockholders Equity | 73.36M | 1K | 23.65K | 1K | 1K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 231.53M | 338.9M | 291.89M | 360.72M | 381.03M |
| Total Debt | 86.16M | 81.45M | 66.5M | 432.72M | 436.69M |
| Net Debt | (234.9M) | (321.02M) | (283.77M) | (23.01M) | (31.02M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.